4-methylphenyl 4-(hydroxyisopropyl)phenyl ether | 86896-99-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methylphenyl 4-(hydroxyisopropyl)phenyl ether
• 英文别名: 2-[4-(4-Methylphenoxy)phenyl]propan-2-ol
• CAS: 86896-99-3
• 化学式: C₁₆H₁₈O₂
• 分子量: 242.318
• InChiKey: BIVJTBLLMUJIQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methylphenyl 4-(hydroxyisopropyl)phenyl ether 在 盐酸 作用下， 以 二氯甲烷 为溶剂， 生成 4-methylphenyl 4-(chloroisopropyl)phenyl ether
  参考文献：
  名称：

  Litvinenko, L. M.; Benndorf, V.; Popova, R. S., Journal of Organic Chemistry USSR (English Translation), 1983, vol. 19, # 4, p. 680 - 683

  摘要：

  DOI：
• 作为产物：
  描述：

  4-methylphenyl 4-(chloroisopropyl)phenyl ether 在 水 作用下， 以 丙酮 为溶剂， 生成 4-methylphenyl 4-(hydroxyisopropyl)phenyl ether
  参考文献：
  名称：

  Litvinenko, L. M.; Benndorf, V.; Popova, R. S., Journal of Organic Chemistry USSR (English Translation), 1983, vol. 19, # 4, p. 680 - 683

  摘要：

  DOI：

文献信息

• IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  申请人：Trabanco-Suarez Andres Avelino

  公开号：US20110009441A1

  公开（公告）日：2011-01-13

  The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I). The compounds according to the invention are positive allosteric modulators of metabotropic receptors-sub-type 2 (‘mGluR2’) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是公式（I）中的新型咪唑并[1,2-a]吡啶衍生物。本发明的化合物是代谢型受体亚型2（“mGluR2”）的阳性变构调节剂，可用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型受体亚型mGluR2的疾病。特别是，这些疾病是来自焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病的群体。本发明还涉及制备这些化合物和组合物的制药组合物和制备过程，以及将这些化合物用于预防和治疗涉及mGluR2的这些疾病的用途。
• LITVINENKO, L. M.;BENNDORF, V.;POPOVA, R. S.;POPOV, A. F.;TORMOSIN, I. I., ZH. ORGAN. XIMII, 1983, 19, N 4, 772-775
  作者：LITVINENKO, L. M.、BENNDORF, V.、POPOVA, R. S.、POPOV, A. F.、TORMOSIN, I. I.

  DOI：——

  日期：——
• US8785486B2
  申请人：——

  公开号：US8785486B2

  公开（公告）日：2014-07-22
• [EN] IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] DÉRIVÉS IMIDAZO[1,2-A]PYRIDINE ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR2
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2009062676A2

  公开（公告）日：2009-05-22

  The present invention relates to novel compounds, in particular novel imidazo[1,2- a]piridine derivatives according to Formula (I). The compounds according to the invention are positive allosteric modulators of metabotropic receptors- subtype 2 ('mGluR2') which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
• Litvinenko, L. M.; Benndorf, V.; Popova, R. S., Journal of Organic Chemistry USSR (English Translation), 1983, vol. 19, # 4, p. 680 - 683
  作者：Litvinenko, L. M.、Benndorf, V.、Popova, R. S.、Popov, A. F.、Tormosin, I. I.

  DOI：——

  日期：——